deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06403735

A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLC1101 Monotherapy in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Sponsor: Qilu Pharmaceutical Co., Ltd.

Conditions Colorectal Cancer Non-small Cell Lung Cancer Pancreatic Cancer Solid Tumor
Interventions QLC1101
Updated 4 times since 2024 Last updated: May 5, 2024 Started: Apr 25, 2024 Primary completion: May 31, 2026 Completion: Apr 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Colorectal Cancer and Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by Qilu Pharmaceutical Co., Ltd. and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotRecruiting~Sep 2025 – present · 11 months · monthly snapshotRecruiting

Change History

4 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

    First recorded

Apr 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Qilu Pharmaceutical Co., Ltd.
Data source: Qilu Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations